Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Up 20.3% in September

Innate Pharma S.A. (NASDAQ:IPHA) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 71,800 shares, an increase of 20.3% from the September 15th total of 59,700 shares. Based on an average daily volume of 7,200 shares, the days-to-cover ratio is presently 10.0 days.

Innate Pharma Trading Up 2.0 %

IPHA traded up $0.04 on Wednesday, hitting $2.07. 2,996 shares of the stock traded hands, compared to its average volume of 8,924. The business has a fifty day moving average price of $2.21 and a two-hundred day moving average price of $2.34. Innate Pharma has a 52 week low of $1.81 and a 52 week high of $3.15.

Analyst Upgrades and Downgrades

IPHA has been the topic of several recent analyst reports. Evercore ISI raised Innate Pharma to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $11.50 target price on shares of Innate Pharma in a research note on Friday, September 13th.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.